nome and kinase-driven signaling pathways [5] , facilitating the use of flies to predict drug 64 response in humans [1, 6] . Second, the ease of breeding and the short (~10 day) life cycle 65 of Drosophila make it possible to carry out efficient mid-throughput chemical screening in 66 a biological system. Third, the screening readout provides a quantitative animal-based 67 measurement of structure-activity relationships (SAR), and further provides information 68 on the therapeutic potential or toxicity of the tested compounds: measurable parameters 69 include survival and multiple phenotypic indicators that depend on kinase activity.
70
One key limitation of Drosophila-based mid-throughput screening platform is that 71 it cannot explore very large chemical libraries [7] , such as the ZINC library which has over 72 750 million purchasable compounds [8] . In contrast, structure-based virtual screening is 73 a fast and inexpensive computational method that can screen large compound libraries,
74
a useful approach to identify unique chemical probes [9] . If the structure of the protein is 75 unknown, virtual screening can be performed against the homology models of the target 76 constructed based on experimentally determined structures. However, the automated 77 construction of homology models-with sufficient accuracy for virtual screening for multi-
78
ple targets simultaneously and the application of molecular docking to signaling net-79 works-remains challenging in particular for highly dynamic targets such as kinases [10, 80 11] and would benefit from a readily accessible whole animal platform.
81
RET is a receptor tyrosine kinase associated with multiple roles in development 82 and homeostasis. Activation of RET by the mutation M918T (analogous to Drosophila rafenib (200 μM) improved overall viability to 3-4% adult survival (P < 0.05).
187
We used this rescue-from-lethality assay to test the efficacy of the eight com- optimized moiety that interacts with the hinge region of the ligand-binding site (Fig. 4C ).
214
Compound 1-2 differs from 1 and 1-1 structurally and was less effective in rescuing 215 ptc>dRet M955T flies, even though it was tested at higher concentrations ( Co-administering sorafenib with 1 and 1-1 led to synergistic improvement of 223 ptc>dRet M955T fly viability (Fig. 4A) 1 also showed activity against aspects of transformation and metastasis in the fly.
236
In the mature larva, the ptc promoter is active in epithelial cells in a stripe pattern in the 237 midline of the developing wing epithelium ( Fig. 4C ; wing disc). ptc-driven dRet activates 238 multiple signaling pathways, promoting proliferation, epithelial-to-mesenchymal transition 239 (EMT), and invasion of dRet M955T -expressing cells beyond the ptc domain [14] (Fig. 4C) .
240
Similar to sorafenib, oral administration of 1 blocked the invasion of dRet M955T -expressing 241 cells into the surrounding wing epithelium (Fig. 4B ).
242
At lower dosage (25 μM), compound 2 weakly rescued ptc>dRet M955T flies (1%; P 243 < 0.05) (Fig. 5A ). Unlike 1, 2 did not act synergistically with sorafenib. This difference was 244 confirmed by the kinase inhibition profile of 2 ( carboxamide group commonly found in type-II KIs (Fig. 6A) . Guided by the docking poses 363 of these compounds, the 1H-indole-2-carboxamide group was combined with an opti-364 mized hinge-binding moiety from sorafenib, to form a significantly more efficacious com-365 pound (i.e., 3). As indicated in the kinase inhibition profile of 3 (Table 3) , it shares part of 366 the target set of its constituents 2 and 2-3.
367
In summary, we demonstrate the potential of combining chemical modeling with 
